Steward Health Care System

Return to Results

A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes

new search

Trial Conditions
  • Diabetes Mellitus II
What is the purpose of this trial?

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

Date & Status

Completed

Who can Participate?

Eligibility

Ages:
18  - 70 

Gender:
Both

Eligibility

Inclusion Criteria:

- 1. HbA1c > 7.0% and ≤ 10.0% obtained at the Screening visit.

- 2. Men and women, 18-70 years of age Established Type 2 diabetes

Exclusion Criteria:

- 1. Symptomatic Type 2 diabetes defined as marked polyuria and polydipsia with
greater than 10% weight loss during the last three months.

- 2. Administration of antihyperglycemic agents (other than thiazolidinediones) for
more than three consecutive or a total of seven non-consecutive days during the four
weeks prior to screening.

- 3. Administration of thiazolidinediones for more than three consecutive or a
total of seven non-consecutive days during the six weeks prior to screening.

Gender: Both
Trial Interventions
Drug
  • Muraglitazar
Other Information

Sponsor: Bristol-Myers Squibb
Phase: Phase 2/Phase 3
Trial ID: NCT00240383
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions